Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK has confirmed that as of 28 February 2026 its issued share capital comprised 4,316,162,488 ordinary shares, of which 244,027,094 are held in treasury, resulting in 4,072,135,394 voting rights. This disclosure, made in line with UK financial transparency rules, provides investors with the official denominator for calculating and reporting significant shareholdings, supporting market transparency and regulatory compliance.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. Headquartered in London and registered in England and Wales, the company operates across international markets with a portfolio spanning multiple therapeutic areas.
Average Trading Volume: 9,035,821
Technical Sentiment Signal: Buy
Current Market Cap: £88.73B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.